Menu
There is an enormous need for migraine treatments. About 110 to 170 million people worldwide suffer from chronic migraines, meaning they experience crippling headaches for fifteen days or more each month, with at least eight days of migraine episodes. Migraines reportedly affect about 15-18% of adult women and 6-8% of men. Consequently, the 2017 GlobalData health report estimates that the migraine drug market will grow by 10% in the seven major markets and be worth around 84 billion Swedish kronor ($8.5 billion) in revenues by 2026.
Chronic migraines cause great personal suffering and force many to take sick leave, which, when you aggregate it, leads to substantial production loss and healthcare costs.
Most treatments are currently based on drug medication, which, in many cases produce none or limited lasting results, and often cause unwanted side effects. Here lies a potential market for Chordate since our Kinetic Oscillation Stimulation (Ozilia® Migraine.) is a drug-free alternative with limited or no side effects.
Botox is also a drug-free alternative, but has side effects and can be costly for patients, which is why we believe Ozilia® Migraine. is a strong alternative for this target group. Botox treatment is performed four times a year, with 30-40 injections per session in the face and around the head. The market for Botox treatment is expected to grow to approximately $3.5 billion by 2027. We therefore operate with the assumption that we can take market shares in that segment relatively quickly, especially since Ozilia® Migraine. has few or no unexpected side effects.
The Ozilia® Migraine. treatment for chronic migraine was the subject of a clinical study at nine clinics in Germany and Finland that was finalized in July, 2022.
On September 8, 2022, a scientific poster was presented at the Migraine Trust International Symposium 2022 in London, reporting a statistically significant reduction in the number of headache days. On November 3, 2022, it was reported that the final analysis of the entire study confirmed statistical significance. Thus, Chordates Ozilia® Migraine treatment is clinically proven to be as good as or better than drug-based alternatives for migraine.
The final study data will be communicated in detail by Chordate when the first scientific article has been approved for publication.
For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of Ozilia®, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.